Payment overview · 2025
General Payments
$2,387.69
90 reported records · 24 companies
Healthcare provider profile · identity verified
David J Bencie, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WINDBER, PA · NPI 1720070436
Verified facts
What the public records show
CMS Open Payments records show David J Bencie, MD received $2,387.69 in general payments during 2025 across 90 reported records.
AstraZeneca Pharmaceuticals LP accounted for 17.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga, Jardiance, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 670 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $411.20 | 17.2% | 9 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $340.28 | 14.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $231.23 | 9.7% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $208.65 | 8.7% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $190.37 | 8.0% | 15 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $181.61 | 7.6% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $141.64 | 5.9% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $81.48 | 3.4% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $79.73 | 3.3% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $76.70 | 3.2% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $75.11 | 3.1% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $55.92 | 2.3% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $55.26 | 2.3% | 3 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $42.39 | 1.8% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $35.45 | 1.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $31.80 | 1.3% | 2 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $25.73 | 1.1% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.37 | 0.9% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $20.90 | 0.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.94 | 0.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.25 | 0.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.62 | 0.7% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $14.66 | 0.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.40 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,175.66 | 88 |
| Travel and Lodging | $191.81 | 1 |
| Education | $20.22 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $242.82 | 5 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $191.81 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $181.61 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $169.18 | 14 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $153.05 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $150.02 | 7 | 2025 |
Source payment records
|
|||||
| WATCHMAN Normalized: watchman |
Device | Boston Scientific Corporation | $148.47 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $141.64 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $137.67 | 12 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $112.81 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $87.72 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $81.48 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $79.73 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $75.11 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $63.51 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $63.51 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $62.53 | 4 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc., Stryker Corporation | $61.18 | 2 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc., Stryker Corporation | $61.18 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $55.26 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $34.54 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $31.59 | 2 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $22.37 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $21.19 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.94 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.62 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 15 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 670 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 156 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 40 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
55 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
156 | 34 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
40 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
156 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
60 | 11 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
670 | 83 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1175 | 251 |
| Levothyroxine Sodium | Levothyroxine Sodium | 890 | 168 |
| Amlodipine Besylate | Amlodipine Besylate | 853 | 174 |
| Furosemide | Furosemide | 826 | 144 |
| Eliquis | Apixaban | 670 | 83 |
| Pantoprazole Sodium | Pantoprazole Sodium | 667 | 143 |
| Metformin Hcl | Metformin Hcl | 628 | 135 |
| Lisinopril | Lisinopril | 585 | 140 |
| Metoprolol Tartrate | Metoprolol Tartrate | 535 | 112 |
| Sertraline Hcl | Sertraline Hcl | 489 | 69 |
| Losartan Potassium | Losartan Potassium | 453 | 106 |
| Potassium Chloride | Potassium Chloride | 437 | 72 |
| Tramadol Hcl | Tramadol Hcl | 437 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 396 | 78 |
| Trazodone Hcl | Trazodone Hcl | 365 | 65 |
| Alprazolam | Alprazolam | 349 | 43 |
| Omeprazole | Omeprazole | 344 | 84 |
| Gabapentin | Gabapentin | 317 | 72 |
| Pravastatin Sodium | Pravastatin Sodium | 316 | 75 |
| Mirtazapine | Mirtazapine | 283 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 280 | 51 |
| Simvastatin | Simvastatin | 265 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 255 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 248 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 247 | 62 |
| Donepezil Hcl | Donepezil Hcl | 242 | 36 |
| Warfarin Sodium | Warfarin Sodium | 237 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 229 | 53 |
| Allopurinol | Allopurinol | 210 | 51 |
| Lorazepam | Lorazepam | 191 | 40 |
| Diclofenac Sodium | Diclofenac Sodium | 176 | 29 |
| Jardiance | Empagliflozin | 156 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 154 | 43 |
| Memantine Hcl | Memantine Hcl | 147 | 21 |
| Famotidine | Famotidine | 146 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 141 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 141 | 20 |
| Prednisone | Prednisone | 140 | 66 |
| Buspirone Hcl | Buspirone Hcl | 131 | 29 |
| Atenolol | Atenolol | 128 | 27 |
| Digoxin | Digoxin | 123 | 26 |
| Xarelto | Rivaroxaban | 120 | 16 |
| Carvedilol | Carvedilol | 113 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 107 | 29 |
| Spironolactone | Spironolactone | 105 | 20 |
| Alendronate Sodium | Alendronate Sodium | 100 | 20 |
| Irbesartan | Irbesartan | 99 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 98 | 13 |
| Myrbetriq | Mirabegron | 96 | 16 |
| Glimepiride | Glimepiride | 95 | 23 |
| Montelukast Sodium | Montelukast Sodium | 90 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 89 | 51 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 89 | 49 |
| Methylprednisolone | Methylprednisolone | 88 | 68 |
| Paroxetine Hcl | Paroxetine Hcl | 88 | 17 |
| Chlorthalidone | Chlorthalidone | 85 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 85 | 21 |
| Cholestyramine | Cholestyramine (With Sugar) | 83 | 17 |
| Lactulose | Lactulose | 83 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 83 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 82 | 14 |
| Entresto | Sacubitril/Valsartan | 81 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 22 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 76 | 41 |
| Divalproex Sodium | Divalproex Sodium | 74 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 73 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 73 | 40 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 71 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 71 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 64 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 63 | suppressed |
| Olanzapine | Olanzapine | 62 | suppressed |
| Amoxicillin | Amoxicillin | 61 | 46 |
| Diazepam | Diazepam | 61 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 61 | suppressed |
| Ozempic | Semaglutide | 60 | 11 |
| Farxiga | Dapagliflozin Propanediol | 59 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 59 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 30 |
| Ezetimibe | Ezetimibe | 57 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 57 | suppressed |
| Primidone | Primidone | 57 | suppressed |
| Trulicity | Dulaglutide | 57 | suppressed |
| Synthroid | Levothyroxine Sodium | 55 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 54 | 15 |
| Azithromycin | Azithromycin | 54 | 48 |
| Tradjenta | Linagliptin | 53 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 51 | 31 |
| Celecoxib | Celecoxib | 51 | 12 |
| Clonazepam | Clonazepam | 51 | suppressed |
| Levetiracetam | Levetiracetam | 51 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 51 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 49 | suppressed |
| Meloxicam | Meloxicam | 49 | 17 |
| Propranolol Hcl | Propranolol Hcl | 46 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 45 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | suppressed |
| Latanoprost | Latanoprost | 44 | suppressed |
| Baclofen | Baclofen | 43 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 15 |
| Finasteride | Finasteride | 43 | 11 |
| Metolazone | Metolazone | 42 | suppressed |
| Rytary | Carbidopa/Levodopa | 41 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | suppressed |
| Glipizide | Glipizide | 39 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | suppressed |
| Bupropion Xl | Bupropion Hcl | 36 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 36 | suppressed |
| Ssd | Silver Sulfadiazine | 35 | suppressed |
| Linzess | Linaclotide | 34 | suppressed |
| Bumetanide | Bumetanide | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Cephalexin | Cephalexin | 31 | 18 |
| Diltiazem Hcl | Diltiazem Hcl | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | suppressed |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Rexulti | Brexpiprazole | 31 | suppressed |
| Loperamide | Loperamide Hcl | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Hydrocortisone | Hydrocortisone | 29 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Calcitriol | Calcitriol | 28 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 27 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Ketoconazole | Ketoconazole | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Dutasteride | Dutasteride | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 17 |
| Metronidazole | Metronidazole | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Mirabegron Er | Mirabegron | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Humalog | Insulin Lispro | 20 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 11 |
| Colchicine | Colchicine | 19 | suppressed |
| Indapamide | Indapamide | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Creon | Lipase/Protease/Amylase | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 18 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Humulin R | Insulin Regular, Human | 17 | suppressed |
| Fentanyl | Fentanyl | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 16 | suppressed |
| Acetic Acid | Acetic Acid | 15 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 15 | 15 |
| Glipizide Er | Glipizide | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 14 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 14 | suppressed |
| Sulindac | Sulindac | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 14 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 12 | suppressed |
| Uloric | Febuxostat | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Alphagan P | Brimonidine Tartrate | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Cialis | Tadalafil | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Probenecid | Probenecid | 11 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
| Trimethoprim | Trimethoprim | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,387.69 · 90 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, CAPVAXIVE, CT THROMBECTOMY SYSTEM KIT, ELIQUIS, FARXIGA, FLOWTRIEVER CATHETER, S, GARDASIL 9, JARDIANCE, KISUNLA, Kerendia, MOUNJARO, NURTEC ODT, Ohtuvayre, QULIPTA, REXULTI, SHINGRIX, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, ULTOMIRIS, VOQUEZNA, VRAYLAR, WATCHMAN, WATCHMAN FLX, Wegovy, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error